Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs, a study to be presented at ESMO 2018 reported.

10 Oct 2018

Researchers design new medicine to treat highly aggressive pancreatic cancer

A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly disease.

12 Sep 2018

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.

31 Aug 2018

Trial shows PARP inhibitor as novel treatment option for patients with advanced breast cancers

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

16 Aug 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.

30 Jun 2018

AntiCancer's oral drug overcomes gemcitabine resistance in mouse models of human pancreatic cancer

Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.

25 Jun 2018

Flushing the bladder with common chemotherapy drug after surgery can reduce bladder cancer recurrence

Flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning, according to a major study by SWOG, an international clinical trials network funded by the National Cancer Institute.

9 May 2018

Genentech researchers uncover epigenetic regulator of pancreatic cancer cells

Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin.

11 Dec 2017

PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations

8 Dec 2017

New research can help develop better chemotherapy treatments for pancreatic cancer

Tal Danino, a professor at the Data Science Institute, is conducting research that could help scientists combat the most lethal of cancers: pancreatic cancer.

6 Oct 2017

Research shows how bacteria inactivate common drug used to treat cancers

To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic tumors.

18 Sep 2017

Researchers define how cancer drug works in cells, mice and man

Science is very good at determining how drugs work in experimental models. New research out of Dartmouth's Norris Cotton Cancer Center led by Alan Eastman, PhD, helps to bridge the gap when it comes to ensuring that drugs work by the same mechanism in human patients.

7 Sep 2017

Bone metastasis-targeting drug shows potential as new therapeutic strategy for osteosarcoma

The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.

13 Jul 2017

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

New research presented at the American Society of Clinical Oncology 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma.

6 Jun 2017